Day: March 30, 2023

EIP Pharma and Diffusion Pharmaceuticals Announce Merger Agreement to Create Leading CNS-focused Company Treating Neurodegenerative Diseases

Written by Customer Service on March 30, 2023. Posted in Mergers And Acquisitions.

Combined company will pursue late-stage clinical development of oral neflamapimod for the treatment of dementia with Lewy bodies EIP Pharma to initiate in 2Q 2023 a Phase 2b clinical study, funded in part by a $21 million grant from the National Institute of Aging Combined company expected to have a cash runway through Phase 2b clinical data and to the end of 2024 Transaction has unanimous support of both EIP Pharma and Diffusion Boards of Directors BOSTON and CHARLOTTESVILLE, Va., March 30, 2023 (GLOBE NEWSWIRE) — EIP Pharma Inc. (EIP Pharma), a privately held clinical-stage company focused on developing treatments for neurodegenerative diseases, and Diffusion Pharmaceuticals Inc. (Diffusion or Diffusion Pharmaceuticals) (NASDAQ: DFFN), today announced that the companies have entered into a definitive merger agreement for an all-stock...

Centessa Pharmaceuticals Reports Recent Business Progress and Financial Results for the Fourth Quarter and Full-Year 2022

Written by Customer Service on March 30, 2023. Posted in Earnings Releases And Operating Results.

– Initiated registration program for SerpinPC to treat hemophilia B; Enrolling subjects in PRESent-5, observational study – – First subject dosed in Phase 1/2a clinical trial for LB101, a PD-L1xCD47 LockBody® to treat solid tumors; Preclinical data from second LockBody program targeting PD-L1xCD3 expected in 2023 – – Nominated ORX750, an orally administered, selective orexin receptor-2 (OX2R) agonist, as product candidate with the potential to be a best-in-class therapy to treat narcolepsy and other sleep disorders; ORX750 profile to be presented at scientific meeting in 2023 – – Cash runway into 2026 – BOSTON and LONDON, March 30, 2023 (GLOBE NEWSWIRE) — Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company focused on discovering and developing medicines that are transformational for patients,...

Renalytix Reports Second Quarter and First Half Fiscal Year 2023 Financial Results

Written by Customer Service on March 30, 2023. Posted in Earnings Releases And Operating Results.

LONDON and SALT LAKE CITY, March 30, 2023 (GLOBE NEWSWIRE) — Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, today reported financial results for the fiscal second quarter and first half ended December 31, 2022. Recent Highlights (including post period events)Expanded insurance coverage for KidneyIntelX including:One of the largest not-for-profit health insurers covering over three million lives in the Northeast U.S. Largest private payer in Illinois with over eight million members 35 state Medicaid plans including recent additions of Texas and FloridaAchieved Medicare payment for KidneyIntelX through the individual claims review (ICR) process...

Stran & Company Achieves 48.5% Increase in Revenue for the 2022 Fiscal Year and Returns to Profitability for the Fourth Quarter of 2022

Written by Customer Service on March 30, 2023. Posted in Earnings Releases And Operating Results.

Achieves Record Revenue of $18.3 million and Net Income of $903,000 for the Fourth Quarter of 2022 Conference call to be held today at 10:00 AM ET QUINCY, Mass., March 30, 2023 (GLOBE NEWSWIRE) — Stran & Company, Inc. (“Stran” or the “Company”) (NASDAQ: SWAG) (NASDAQ: SWAGW), a leading outsourced marketing solutions provider that leverages its promotional products and loyalty incentive expertise, today provided a business update and reported financial results for the year ended December 31, 2022. Andy Shape, President and CEO of Stran, commented, “Throughout 2022, we continued to grow and generated revenue of approximately $59.0 million for the 2022 fiscal year, a 48.5% increase compared to 2021. Importantly, we returned to profitability for the fourth quarter of 2022, generating approximately $18.3...

K92 Mining Announces Strong 2022 Q4 and Annual Financial Results – Record Cash Balance, Revenue, Ore Mined and Ore Processed; Cash Cost and AISC Better Than Guidance

Written by Customer Service on March 30, 2023. Posted in Earnings Releases And Operating Results.

Figure 1 Quarter Production ChartFigure 2 Quarterly Operations and DevelopmentFigure 3 Ore Processed Records ChartVANCOUVER, British Columbia, March 30, 2023 (GLOBE NEWSWIRE) — K92 Mining Inc. (“K92” or the “Company”) (TSX: KNT; OTCQX: KNTNF) is pleased to announce financial results for the three and twelve months ended December 31, 2022. SafetyStrong focus on safety with zero Lost Time Injuries (“LTI”) during the quarter and one of the best safety records in the Australasia region since commencement of operations. Proactive and focused management of COVID-19. K92 has continuously operated throughout the COVID-19 pandemic, and has strong preventative and response plans in place.ProductionFourth Quarter 2022Record quarterly ore processed of 121,686 tonnes or 1,323 tonnes per day (“tpd”), significantly exceeding the...

Trevena Reports Fourth Quarter 2022 Results and Provides Business Update

Written by Customer Service on March 30, 2023. Posted in Earnings Releases And Operating Results.

Company announces initial topline OLINVYK data including GI and cognitive outcomes, and length of stay data from ~200 patient real-world clinical outcomes study TRV045, a novel S1P receptor modulator, continues to advance as a potential treatment for epilepsy, diabetic neuropathic pain and other CNS disorders, with two proof-of-concept studies expected to complete enrollment by mid-2023 Cash balance of $38.3 million at year end 2022 Company to host conference call today, March 30, 2023 at 8:00 a.m. ET CHESTERBROOK, Pa., March 30, 2023 (GLOBE NEWSWIRE) — Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today reported its financial results for the fourth quarter ended December 31, 2022 and provided...

InspireMD Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Business Update

Written by Customer Service on March 30, 2023. Posted in Earnings Releases And Operating Results.

– 2022 CGuard EPS revenue of $5.1 million increased 18.9% over 2021 – – Resumed shipments of CGuard EPS to CE Mark territories under the pre-existing Medical Device Directive (MDD) regulatory framework; Company anticipates re-certification under new Medical Device Regulation (MRD) framework in coming weeks – – Continued enrollment in the C-Guardian US IDE trial, with 20 sites currently enrolling patients; on track to complete enrollment by approximately end of Q2 2023 – —Management to host investor conference call today, March 30, at 8:30am ET— TEL AVIV, Israel, March 30, 2023 (GLOBE NEWSWIRE) — InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for treatment of carotid artery disease (CAD) and prevention of stroke...

Avadel Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results

Written by Customer Service on March 30, 2023. Posted in Earnings Releases And Operating Results.

• LUMRYZ™ NDA amendment filed March 1 requesting FDA final approval • Received FDA authorization to import LUMRYZ in advance of final approval decision; shortens timeline between potential approval and product availability • Secured $200 million of capital to fund the launch of LUMRYZ and extended the maturity of $96.2 million of the convertible notes to 2027 • Launch preparations on track to support U.S. commercial launch of LUMRYZ • Management to host a conference call today at 8:30 a.m. ET DUBLIN, Ireland, March 30, 2023 (GLOBE NEWSWIRE) — Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today provided a corporate update and announced its financial results for the fourth quarter ended December 31, 2022. “2023 is shaping up to be a significant...

Osisko Green Acquisition Limited Reports 2022 Financial Results

Written by Customer Service on March 30, 2023. Posted in Public Companies.

NOT FOR DISTRIBUTION TO U.S. NEWSWIRES OR DISSEMINATION IN THE UNITED STATES TORONTO, March 30, 2023 (GLOBE NEWSWIRE) — Osisko Green Acquisition Limited (TSX:GOGR) (the “Corporation“) is reporting its financial results as at and for the year ended December 31, 2022. The Corporation is also announcing that there are no material updates regarding its search for target businesses with which it may complete its qualifying acquisition. The Corporation’s audited annual financial statements, along with the accompanying management’s discussion and analysis have been filed on the System for Electronic Document Analysis and Retrieval and may be viewed by interested parties under the Corporation’s profile at www.sedar.com or the Corporation’s website at www.osiskogreen.com. About Osisko Green Acquisition...

Resolutions from Novozymes A/S’ Extraordinary Shareholders’ Meeting on 30 March 2023

Written by Customer Service on March 30, 2023. Posted in Public Companies.

Please read the announcement in PDFAttachment2023_51_Novozymes_extraordinary_shareholders_meeting_resolutions

Day: March 30, 2023

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals